NetworkNewsBreaks – CytoDyn Inc. (CYDY) Announce
Post# of 154835
(Total Views: 2433)
Posted On: 05/18/2017 4:15:15 AM
NetworkNewsBreaks – CytoDyn Inc. (CYDY) Announces Treatment of First Patient in Phase 2 Trial of PRO 140 for Graft versus Host Disease
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced the treatment of the first patient in its phase 2 clinical trial of PRO 140 for Graft versus Host Disease (GvHD), which represents its leading immunologic indication for the candidate. The multicenter, 60-patient study aims to evaluate the safety and efficacy of PRO 140 in treating GvHD, a potentially life-threatening complication affecting patients requiring a bone marrow transplant due to depleted immune systems. Currently, these transplant patients have just a 40-60% one-year survival rate, and relapsed GvHD is the leading cause of death. “We selected the transplantation indication called GvHD as our first expansion of PRO 140 into a non-HIV clinical indication because it targets the CCR5 receptor, which is known to be an important mediator of GvHD, especially in the organ damage that is the usual cause of death,” Denis R. Burger, Ph.D., chief science officer of CytoDyn, stated in the news release. “We plan to explore additional opportunities to expand the clinical applications of PRO 140 to those indications where CCR5 plays an important role, namely certain autoimmune diseases and cancer.” If the company receives positive results from its phase 2 study evaluating PRO 140 for the treatment of GvHD, CytoDyn expects to file for Breakthrough Designation with the FDA in order to expedite the commercialization of its lead candidate in this clinical indication.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced the treatment of the first patient in its phase 2 clinical trial of PRO 140 for Graft versus Host Disease (GvHD), which represents its leading immunologic indication for the candidate. The multicenter, 60-patient study aims to evaluate the safety and efficacy of PRO 140 in treating GvHD, a potentially life-threatening complication affecting patients requiring a bone marrow transplant due to depleted immune systems. Currently, these transplant patients have just a 40-60% one-year survival rate, and relapsed GvHD is the leading cause of death. “We selected the transplantation indication called GvHD as our first expansion of PRO 140 into a non-HIV clinical indication because it targets the CCR5 receptor, which is known to be an important mediator of GvHD, especially in the organ damage that is the usual cause of death,” Denis R. Burger, Ph.D., chief science officer of CytoDyn, stated in the news release. “We plan to explore additional opportunities to expand the clinical applications of PRO 140 to those indications where CCR5 plays an important role, namely certain autoimmune diseases and cancer.” If the company receives positive results from its phase 2 study evaluating PRO 140 for the treatment of GvHD, CytoDyn expects to file for Breakthrough Designation with the FDA in order to expedite the commercialization of its lead candidate in this clinical indication.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)